Wednesday, May 07, 2008

Amgen Announces Voting Results of Annual Meeting of Stockholders

THOUSAND OAKS, Calif. – May 7, 2008 – Amgen (NASDAQ:AMGN), today announced results of voting at the company’s Annual Meeting of Stockholders, held at the Four Seasons Hotel Westlake Village in Westlake Village, Calif. Approximately 86.9 percent of outstanding shares were represented at the meeting.

Posted in Press Releases

Tuesday, May 06, 2008

Amgen to Participate in CHMP Oncology Scientific Advisory Group Meeting in May

THOUSAND OAKS, Calif. – May 6, 2008 – Amgen (NASDAQ:AMGN) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has requested Amgen and other erythropoiesis-stimulating agent (ESA) marketing authorization holders to participate in a closed meeting of the Scientific Advisory Group on Oncology (SAG-O) on May 15.

Posted in Press Releases

Thursday, May 01, 2008

Amgen to Participate in Dermatologic and Ophthalmic Drugs Advisory Committee Meeting in June

Company Is in Discussions with FDA About Enbrel(R) (etanercept) in Pediatric Psoriasis

THOUSAND OAKS, Calif. – May 1, 2008 – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has asked the Company to participate in a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) on June 18, 2008. The DODAC will review data supporting the supplemental Biologic License Application (sBLA) submitted by Amgen for the use of ENBREL in treating pediatric patients with chronic moderate to severe plaque psoriasis, who are inadequately controlled with topical therapy or who have received systemic therapy or phototherapy.

Posted in Press Releases, Product News